Bruker (NASDAQ:BRKR) PT Lowered to $60.00 at The Goldman Sachs Group

Bruker (NASDAQ:BRKR) had its price target decreased by The Goldman Sachs Group from $72.00 to $60.00 in a report published on Tuesday, Benzinga reports. The Goldman Sachs Group currently has a sell rating on the medical research company’s stock.

Several other analysts also recently weighed in on the company. Bank of America decreased their target price on Bruker from $95.00 to $90.00 and set a buy rating for the company in a research report on Monday, May 20th. Stifel Nicolaus cut their price target on Bruker from $81.00 to $77.00 and set a hold rating on the stock in a research note on Monday, May 20th. StockNews.com lowered Bruker from a buy rating to a hold rating in a research note on Tuesday, May 21st. Finally, Jefferies Financial Group initiated coverage on Bruker in a research note on Monday, June 3rd. They set a buy rating and a $85.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $81.78.

Bruker Stock Up 4.0 %

NASDAQ:BRKR opened at $63.72 on Tuesday. Bruker has a twelve month low of $53.79 and a twelve month high of $94.86. The company has a market cap of $9.26 billion, a price-to-earnings ratio of 23.17, a price-to-earnings-growth ratio of 2.10 and a beta of 1.20. The stock has a fifty day simple moving average of $68.43 and a 200-day simple moving average of $76.67. The company has a current ratio of 1.81, a quick ratio of 0.91 and a debt-to-equity ratio of 0.95.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.07. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The business had revenue of $721.70 million during the quarter, compared to the consensus estimate of $729.88 million. During the same period last year, the company earned $0.64 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Analysts anticipate that Bruker will post 2.66 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 17th. Shareholders of record on Monday, June 3rd were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 3rd. This represents a $0.20 annualized dividend and a yield of 0.31%. Bruker’s dividend payout ratio (DPR) is presently 7.27%.

Hedge Funds Weigh In On Bruker

Several institutional investors and hedge funds have recently added to or reduced their stakes in BRKR. Linden Thomas Advisory Services LLC grew its stake in shares of Bruker by 16.8% during the second quarter. Linden Thomas Advisory Services LLC now owns 19,357 shares of the medical research company’s stock worth $1,235,000 after acquiring an additional 2,784 shares during the last quarter. CWM LLC grew its stake in shares of Bruker by 165.4% during the second quarter. CWM LLC now owns 4,777 shares of the medical research company’s stock worth $305,000 after acquiring an additional 2,977 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Bruker by 40.7% during the first quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock worth $81,000 after acquiring an additional 248 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in shares of Bruker by 0.6% during the first quarter. DekaBank Deutsche Girozentrale now owns 307,040 shares of the medical research company’s stock worth $28,689,000 after acquiring an additional 1,844 shares during the last quarter. Finally, Cetera Advisors LLC purchased a new stake in shares of Bruker during the first quarter worth about $693,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.